Samuel Klempner, Associate Professor at Harvard Medical School, shared a post on X about a recent article by Navneet S. Majhail et al, adding:
“With interest in PD-1xVEGF across cancers we add some data from Ram and Pembro.
Distinct spatially resolved TME trajectories define benefit from ramucirumab + pembro in refractory PD-L1+ gastric cancer.”
Title: Distinct spatially resolved tumor microenvironment trajectories define benefit from ramucirumab plus pembrolizumab in refractory PD-L1+ gastric cancer
Authors: Navneet S. Majhail, Tonya Cox, Stephanie Larson, Minoo Battiwalla, Aravind Ramakrishnan, Paul Shaughnessy, Michael Tees, Nicole Zahradka, Matt Wilkes, Jeremy Pantin
Read the Full Article on Cancer Immunology Research
More posts featuring Sam Klempner.